AEM vs B

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

The Advanced Deterministic Scorecard reveals a mixed financial profile: the Piotroski F-Score of 4/9 indicates borderline financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong profitability and growth metrics—evidenced by 23.2% YoY revenue growth and 175.7% earnings growth—the stock trades above its Graham Number of $26.91 at $51.08, reflecting rich valuation. Solid balance sheet metrics like a 0.14 Debt/Equity ratio and 2.94 Current Ratio support resilience, but weak technical trend (10/100) and inconsistent analyst targets temper bullishness. The stock's premium valuation appears justified by strong historical performance and sector outperformance, yet sustainability depends on maintaining high growth and disciplined capital allocation.